Novel GLP-1 receptor agonist peptides

A compound of formula (I): (I) wherein Q is optionally substituted phenyl or monocyclic heteroaryl; x is an integer from 1 to 3; R1 & R2 are hydrogen or C1-6 alkyl, or form a ring; aa1 is an amino acid; G is glycinyl;T is L-threoninyl; aa2 is an amino acid; W is L-serinyl or 2,3-diaminopropionyl...

Full description

Saved in:
Bibliographic Details
Main Authors Miles Stuart Congreve, Jonathan Stephen Mason, Andrea Bortolato, Steve Andrews
Format Patent
LanguageEnglish
Published 08.09.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A compound of formula (I): (I) wherein Q is optionally substituted phenyl or monocyclic heteroaryl; x is an integer from 1 to 3; R1 & R2 are hydrogen or C1-6 alkyl, or form a ring; aa1 is an amino acid; G is glycinyl;T is L-threoninyl; aa2 is an amino acid; W is L-serinyl or 2,3-diaminopropionyl; aa3 is an amino acid; aa4 is an amino acid; aa5 is a linking group; Z is hydrogen, -COOR8 or -CONR9R10; R8, R9 and R10 are hydrogen or C1-6 alkyl; or a tautomeric or stereochemically isomeric form or a prodrug, salt or zwitterion thereof. The compounds of formula (I) are Glucagon-like peptide-1 (GLP-1) receptor agonist peptides and are useful in treating diseases or conditions mediated by insulin, such as diabetes mellitus type 1 or 2. The invention further relates to compositions containing said peptides and processes for their preparation.
Bibliography:Application Number: GB20150022431